Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) announced the publication of soquelitinib trial data in Blood, the journal of the American Society of Hematology, on August 27, 2026. The Phase 1/1b study evaluated soquelitinib in 75 patients with various T cell lymphomas, all of whom had received a median of three prior therapies.
Dosing ranged from 100 mg to 600 mg twice daily, with a 200 mg twice-daily expansion dose selected based on biomarker studies. In the 36-patient cohort receiving the 200 mg dose, six patients achieved complete responses and three achieved partial responses. Among the subgroup of 24 patients with one to three prior therapies, nine achieved objective responses—six complete and three partial—with a median progression-free survival of 6.2 months and a median overall survival of 28.1 months.
Soquelitinib was reported to be well tolerated across all dose cohorts up to 600 mg twice daily, with no dose-limiting toxicities, myelosuppression, or immunosuppression observed. The drug’s mechanism involves selective ITK inhibition, driving Th1 skewing while blocking Th2 and Th17 differentiation, supported by in vitro studies and biomarker analyses showing increased Th1 cells and reduced serum IL-5.
Corvus is advancing soquelitinib into a Phase 3 registration trial in relapsed or refractory peripheral T cell lymphoma, targeting 150 patients. The randomized controlled trial will compare soquelitinib to physician’s choice of belinostat or pralatrexate, with progression-free survival as the primary endpoint. Additional trials are planned, including a Phase 2 study in atopic dermatitis and future studies in hidradenitis suppurativa and asthma.
The company holds orphan drug designation for soquelitinib in T cell lymphoma and fast track designation for its use in relapsed or refractory peripheral T cell lymphoma after at least two prior systemic therapies.
